Trial Profile
Observational Study of the Use of KRYSTEXXA (Pegloticase) in Adult Hyperuricemic Patients With Gout Refractory to Conventional Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Pegloticase (Primary)
- Indications Gout
- Focus Adverse reactions
- Acronyms EyesOnGOUT
- Sponsors Crealta Pharmaceuticals; Horizon Pharma; Savient Pharmaceuticals
- 17 Jul 2017 Status changed from active, no longer recruiting to completed.
- 09 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 30 Jun 2016 Planned End Date changed from 1 Jul 2015 to 1 Jul 2017.